
Thermo Fisher Scientific Phospho-VAV1 (Tyr160) Polyclonal Antibody
인간 VAV1 단백질의 Tyr160 인산화 부위를 인식하는 폴리클로날 항체입니다. Western blot 및 면역침강(IP)에 사용 가능하며, 항원 친화 크로마토그래피로 정제되었습니다. -20°C에서 보관하며 연구용으로만 사용됩니다.
- 카탈로그번호
- 44482
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Phospho-VAV1 (Tyr160) Polyclonal Antibody
Applications and Tested Dilutions
| Application | Tested Dilution | Publications |
|---|---|---|
| Western Blot (WB) | 1:1,000 | View 6 publications |
| Immunoprecipitation (IP) | Assay-dependent | View 1 publication |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Published Species | Human, Mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | A chemically synthesized phosphopeptide derived from a region of human Vav1 that contains tyrosine 160 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification | Antigen affinity chromatography |
| Storage Buffer | Dulbecco’s PBS, pH 7.3, with 1 mg/mL BSA |
| Contains | 0.05% sodium azide |
| Storage Conditions | -20°C |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
| RRID | AB_2533661 |
Target Information
This gene encodes the coiled-coil containing protein optineurin. Optineurin may play a role in normal-tension glaucoma and adult-onset primary open angle glaucoma. It interacts with adenovirus E3-14.7K protein and may utilize tumor necrosis factor-alpha or Fas-ligand pathways to mediate apoptosis, inflammation, or vasoconstriction. Optineurin may also function in cellular morphogenesis, membrane trafficking, vesicle trafficking, and transcription activation through its interactions with the RAB8, huntingtin, and transcription factor IIIA proteins. Alternative splicing results in multiple transcript variants encoding the same protein.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.

